News
![Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical
![IMV to Participate at Two Upcoming Investor Conferences](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
IMV to Participate at Two Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV’s executive
![ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr
![QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation
![QIAGEN und DiaSorin starten Markteinführung nach FDA-Zulassung für LIAISON QuantiFERON-TB Gold Plus Test auf LIAISON-Plattformen](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN und DiaSorin starten Markteinführung nach FDA-Zulassung für LIAISON QuantiFERON-TB Gold Plus Test auf LIAISON-Plattformen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE Italia Mid Cap: DIA) gaben heute die US-Markteinführung eines automatisierten Workflows für QuantiFERON-TB Plus (QFT-Plus), den
![Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four
![Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial
![Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today
![Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference
Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure’s Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr
![Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005728/en/
Iron Deficiency Day is an international event which
![VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005734/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today
![ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at the 61st American Society of
![The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion
The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash
![SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS®
![Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells
Regulatory News:
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today
![QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutions](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an agreement with LabCorp® (NYSE: LH) to extend their current QIAGEN Clinical Insights (QCI) license with QIAGEN’s Human Gene
![Paion: Marktzulassung von Remimazolam ist auf den Weg gebracht](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Paion: Marktzulassung von Remimazolam ist auf den Weg gebracht
Wie das kleine deutsche Specialty-Pharma-Unternehmen Paion (WKN: A0B65S) heute vermeldete, hat man nun endlich den Marktzulassungsantrag für Remimazolam in der Kurzsedierung bei der Europäischen
![Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology
![Heat Biologics: Aktie explodiert - darauf ist jetzt zu achten!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Heat Biologics: Aktie explodiert - darauf ist jetzt zu achten!
Der Aktienkurs von Heat Biologics (WKN: A2JB4Y) erlebt derzeit ein wahres Auf und Ab. Wohin die Reise letztendlich geht, entscheiden die jetzt veröffentlichten Topline-Daten zur
![Prothena: NBC-Bonusaktie marschiert +60% in 5 Wochen](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Prothena: NBC-Bonusaktie marschiert +60% in 5 Wochen
Am 29. August stellten wir NBC-Mitgliedern die irische Prothena (WKN: A1KAVV) als Bonusaktie vor. Zu diesem Zeitpunkt hatte die Value-Perle unsere gewünschte Kaufzone bis 7,50 USD bereits
![Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted
![Biofrontera: Aktie crasht nach heftiger Gewinnwarnung](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Biofrontera: Aktie crasht nach heftiger Gewinnwarnung
Die Wachstumsstory bekommt Risse: Biofrontera (WKN: 604611) legt heute seinen 9-Monatsbericht zu den bekannten Eckzahlen vor, die im Oktober wenige Anleger überzeugten (wir berichteten).
In den
![Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at